Life sciences

Riewerts and Reyes on why siloed risk functions are breaking down — and how AI, integration, and “risk intelligence” are reshaping life sciences compliance.

A new study found proposed Medicare drug pricing models may rely on prices from relatively few international markets.

Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.

Justices rule drugmakers cannot be liable for delaying safer alternatives when existing products are FDA approved and nondefective.

Our in-brief roundup of notable healthcare and life sciences stories from the last two weeks.

As Anthropic pushes deeper into life sciences, the FDA is sharpening rules around AI‑enabled research and the use of computational predictions in regulated development pipelines.

The EU has tasked EQT to head the new €5 billion ($5.8 billion) fund aimed at keeping Europe’s most promising tech companies from scaling abroad.

GRIP will partner with Informa Connect’s Pharmaceutical Compliance Congress: Canada to capture how compliance leaders are helping the industry innovate responsibly amid regulatory complexity.